About Harrow, Inc.
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee. Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer.
2BB score and signals
Harrow, Inc.’s current 2BB score is 60 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 77 | High |
| Momentum | 77 | Improving |
| Financial strength | 39 | Weak |
| Quality | 99 | Very Strong |
| Risk | 44 | Moderate |
Company facts
| CEO | Mark L. Baum Esq. |
| Headquarters | Nashville, Tennessee, United States |
| Founded | 2012 |
| Employees | 373 |
| 52-week range | $26.96 – $54.85 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-03-01 | — | 0.918 | — | $138.90M |
| 2026-11-09 | — | 0.2333 | — | $101.05M |
| 2026-08-10 | -0.34 | -0.1836 | $70.66M | $71.75M |
| 2026-05-11 | -0.74 | -0.4095 | $44.20M | $53.47M |
Related companies
